Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   Enterobacterales Carbapenem Breakpoint (BIT)
AR Bank # 0013 Escherichia coli
Study ID: BIT-13

Biosample Accession #: SAMN04014854

   
MLST: 254(Pasteur), 62(Achtman)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Enterobacterales Carbapenem Breakpoint (BIT)  |  Piperacillin-tazobactam +aminoglycosides for Enterobacterales (PTA) (Custom)  |  PTA - BIT set only (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 2S
Ampicillin >32R
Ampicillin/sulbactam 116I
Aztreonam <=2S
Aztreonam/avibactam 1<=0.03---
Cefazolin >8R
Cefepime 4SDD
Cefepime/zidebactam 20.06---
Cefotaxime >64R
Cefotaxime/clavulanic acid 1<=0.5---
Cefoxitin <=2S
Ceftazidime <=1S
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 1<=0.5---
Ceftolozane/tazobactam 1<=0.5S
Ceftriaxone >32R
Ciprofloxacin <=0.25S
Colistin 50.5I
Doripenem <=0.12S
Eravacycline 30.06S
Ertapenem <=0.12S
Gentamicin >16R
Imipenem <=0.5S
Imipenem/relebactam 10.06S
Imipenem+chelators 4<=0.25---
Levofloxacin <=0.25S
Meropenem <=0.12S
Meropenem-vaborbactam 1<=0.5S
Minocycline <=4S
Nitrofurantoin <=16S
Piperacillin/tazobactam 1<=4S
Plazomicin 0.5S
Tetracycline >32R
Tigecycline 3<=0.5S
Tobramycin 8R
Trimethoprim/sulfamethoxazole 1>8R
S – I –R Interpretation (INT) derived from CLSI 2024 M100 S34
1 Reflects MIC of first component
2 Cefepime to zidebactam ratio (1:1)
3 Based on FDA break points
4 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
5 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-IId, aadA2
Beta-lactam CTX-M-14, EC-5, TEM-1
Efflux pumps/Other EMRD
Macrolide-Lincosamide-Streptogramin MDF(A), mph(A)
Phenicols/Bicyclomycins catA1
Sulfonamides sul1
Tetracyclines tet(A), tet(R)
Trimethoprim dfrA12
 
Disclaimer:
AR gene prediction was performed using ARG-ANNOT, ResFinder and NCBI (ResGANNCBI) databases accessed on 2021-05-07. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of used database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. *Presence of Efflux Pump may not be associated with resistance. *MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacterales, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified and "submitted".
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
01/08/24MIC was updated with a new value for Minocycline: from '---' to '<=4'
04/10/23INT was updated with a new value for Tobramycin: from 'I' to 'R'
Top of Page
TOP